SciELO - Scientific Electronic Library Online

 
vol.14 número2Cambios en la masa ósea en una población infantil con diabetes mellitus tipo 1. Estudio longitudinalDescripción de los pacientes atendidos en la Escuela de Prevención de Fracturas y Caídas en el contexto de una Fracture Liaison Service. FLS Anoia índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista de Osteoporosis y Metabolismo Mineral

versão On-line ISSN 2173-2345versão impressa ISSN 1889-836X

Resumo

GIFRE, L et al. Effect of treatment with denosumab for 24 months in individuals with recent spinal cord injury with osteoporosis. Rev Osteoporos Metab Miner [online]. 2022, vol.14, n.2, pp.88-92.  Epub 12-Set-2022. ISSN 2173-2345.  https://dx.doi.org/10.4321/s1889-836x2022000200005.

Introduction:

Osteoporosis development is a frequent complication associated with spinal cord injury (SCI), especially at the sublesional level. However, at present, data on its treatment are scarce.

Aim:

To analyze bone mineral density (BMD) and bone turnover markers (BTM) after 2-year treatment with denosumab in individuals with SCI-related osteoporosis.

Methods:

Prospective study including patients with recent SCI and related osteoporosis treated with denosumab for 24 months. In all patients, BTMs (bone ALP, sCTX and PINP), 25-OH-vitamin D levels and lumbar and femoral BMD were assessed at baseline and at 12 and 24 months.

Results:

13 patients (aged 39±15 years) with recent SCI (mean duration of 15 months) and osteoporosis treated with denosumab for 24 months were included. Patients showed a significant increase in BMD at lumbar spine and proximal femur after 12 months of treatment with denosumab, with a further increase in BMD at 24 months of follow-up, reaching an increase of 9.1% in lumbar spine, 4.4% in femoral neck and 5.3% total femur, respectively. BTM significantly decrease at 12 months and remained decreased at 24 months of follow-up. No skeletal fractures or treatment-related adverse events were observed during follow-up.

Conclusions:

Treatment with denosumab during 24 months increases lumbar and femoral BMD and decreases BTMs in patients with recent SCI. Denosumab may be a promising therapeutic option in SCI-related osteoporosis.

Palavras-chave : denosumab; osteoporosis; spinal cord injury; bone mineral density; bone turnover markers.

        · resumo em Espanhol     · texto em Espanhol | Inglês     · Inglês ( pdf ) | Espanhol ( pdf )